Company History

  • April 2010

    Shandong Taibang was designated as a “National Center of Excellence for New Drug and Technology Development” by the Department of Science and Technology of Shandong province, making it eligible to implement and advance major drug development strategies proposed by China's Ministry of Science and Technology.
  • December 2009

    China Biologic began trading on NASDAQ under the symbol of “CBPO.” Senior management rang the opening bell at the NASDAQ MarketSite on December 15.
  • November 2009

    Forbes magazine named China Biologic to its annual list of Asia's "200 Best Under a Billion."
  • July 2009

    China Biologic acquired a 35% equity interest in Xi'an Huitian Blood Products Co., Ltd. (“Huitian”), gaining access to three new plasma stations with 80 metric tons in annual plasma collection volume and one plasma manufacturing facility with a 200 metric ton capacity.
FirstPage | PreviousPage | NextPage | LastPage CurrentPageIndex:8 [2] [3] [4] [5] [6] [7] [8] [9] [10] 
© 2017 China Biologic Products Holdings, Inc. All Rights Reserved.